The effect of Terazosin and Tolterodine in the treatment of double J stent-related urinary symptoms

Comparison of the effect of Terazosin, Tolterodine, and their combination in the treatment of double J stent-related urinary symptoms in patients with ureteral stones

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160924029935N2

Enrollment

Registered

2020-05-26

Start date

2019-03-20

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lower urinary tract symptoms, ureteral stone. Urinary calculus, unspecified

Interventions

Intervention 1: Intervention group: 1

Tab Terazosin 2 mg BID for 2 weeks. Intervention 2: Intervention group: 2

Tab Tolterodine 2 mg BID for 2 weeks. Intervention 3: Intervention group: 3, Tab including Terazosin 2 mg+Tolterodine 2mg, BID for 2 weeks. Intervention 4: Control group: Tab Placebo (identical-lookin

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: patients with ureteral stones undergoing unilateral transurethral lithotripsy

Exclusion criteria

Exclusion criteria: History of major urinary surgery Benign prostate hyperplasia under medical therapy Overactive bladder Drug sensitivity

Design outcomes

Primary

Measure	Time frame
Ureteral stent urinary symptoms. Timepoint: 2 weeks after intervention. Method of measurement: Ureteral Stent Symptoms Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Akhavan Rezayat

Mashhad University of Medical Sciences

akhavanra@mums.ac.ir+98 51 3840 0001

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026